|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLA2G4C |
Gene summary for PLA2G4C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLA2G4C | Gene ID | 8605 |
| Gene name | phospholipase A2 group IVC | |
| Gene Alias | CPLA2-gamma | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UP65 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8605 | PLA2G4C | HCC1_Meng | Human | Liver | HCC | 1.05e-11 | -3.00e-02 | 0.0246 |
| 8605 | PLA2G4C | HCC2 | Human | Liver | HCC | 3.93e-18 | 5.11e+00 | 0.5341 |
| 8605 | PLA2G4C | S028 | Human | Liver | HCC | 1.07e-13 | 6.59e-01 | 0.2503 |
| 8605 | PLA2G4C | S029 | Human | Liver | HCC | 5.12e-12 | 7.51e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:005123521 | Liver | HCC | maintenance of location | 185/7958 | 327/18723 | 1.70e-07 | 3.12e-06 | 185 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:00464342 | Liver | HCC | organophosphate catabolic process | 89/7958 | 155/18723 | 1.24e-04 | 1.03e-03 | 89 |
| GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
| GO:00199152 | Liver | HCC | lipid storage | 53/7958 | 87/18723 | 4.01e-04 | 2.71e-03 | 53 |
| GO:0036151 | Liver | HCC | phosphatidylcholine acyl-chain remodeling | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
| GO:000167621 | Liver | HCC | long-chain fatty acid metabolic process | 60/7958 | 112/18723 | 1.17e-02 | 4.28e-02 | 60 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| hsa052316 | Liver | HCC | Choline metabolism in cancer | 57/4020 | 98/8465 | 2.14e-02 | 4.90e-02 | 2.72e-02 | 57 |
| hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| hsa0523111 | Liver | HCC | Choline metabolism in cancer | 57/4020 | 98/8465 | 2.14e-02 | 4.90e-02 | 2.72e-02 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLA2G4C | SNV | Missense_Mutation | rs771908409 | c.1084N>A | p.Ala362Thr | p.A362T | Q9UP65 | protein_coding | tolerated(0.28) | benign(0.103) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| PLA2G4C | insertion | Frame_Shift_Ins | novel | c.1415_1416insTCCGGGGCCTGATTGTGCCACTTCCCACAGTGGG | p.Val473ProfsTer27 | p.V473Pfs*27 | Q9UP65 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| PLA2G4C | SNV | Missense_Mutation | rs368409006 | c.649N>A | p.Ala217Thr | p.A217T | Q9UP65 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PLA2G4C | SNV | Missense_Mutation | rs775130071 | c.181N>A | p.Gly61Arg | p.G61R | Q9UP65 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PLA2G4C | SNV | Missense_Mutation | rs145766964 | c.1316G>A | p.Arg439His | p.R439H | Q9UP65 | protein_coding | tolerated(0.6) | benign(0.013) | TCGA-AA-3941-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLA2G4C | SNV | Missense_Mutation | c.1124A>G | p.Tyr375Cys | p.Y375C | Q9UP65 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PLA2G4C | SNV | Missense_Mutation | c.4N>T | p.Arg2Cys | p.R2C | Q9UP65 | protein_coding | probably_damaging(0.942) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| PLA2G4C | SNV | Missense_Mutation | c.1136N>A | p.Gly379Asp | p.G379D | Q9UP65 | protein_coding | tolerated(1) | benign(0.03) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLA2G4C | SNV | Missense_Mutation | novel | c.1289C>A | p.Thr430Asn | p.T430N | Q9UP65 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AF-2693-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PLA2G4C | SNV | Missense_Mutation | c.1276N>A | p.Asp426Asn | p.D426N | Q9UP65 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |